CGT

210개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved210 programs
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 1

Anti-CD19 and anti-CD20 bicistronic CAR T- cells (Anti-CD19 and anti-CD20 bicistronic CAR T- cells)

Chronic Lymphocytic Leukemia; B-Cell Chronic Lymphocytic Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleShenzhen Institute for Innovati…Phase 1

Anti-CD19-CAR transduced T cells (Anti-CD19-CAR transduced T cells)

Chronic Lymphocytic Leukemia; Acute Lymphocytic Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleShanghai Changzheng HospitalPreclinical

Anti-CD19-CD3E-CAR-T cells (Anti-CD19-CD3E-CAR-T cells)

Systemic Lupus Erythematosus (SLE); Sjogren's Syndrome · CD19

#CD19#CGT#Preclinical#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleSumithira VasuPhase 1

Anti-CD19/CD20/CD22 CAR T-Cells (Anti-CD19/CD20/CD22 CAR T-Cells)

Recurrent Acute Lymphoblastic Leukemia; Recurrent B Acute Lymphoblastic Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleJiangsu Topcel-KH Pharmaceutica…Phase 1

Anti-PD1 armored CD19 CAR-T cells (Anti-PD1 armored CD19 CAR-T cells)

Diffuse Large B Cell Lymphoma · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleAFA InsurancePhase 2

Autologous 3rd generation CD19-targeting CAR T cells (Autologous 3rd generation CD19-targeting CAR T cells)

B Cell Lymphoma; B Cell Leukemia · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleMayo ClinicPhase 1

Autologous Anti-CD19 CAR-expressing T-lymphocytes IC19/1563 (Autologous Anti-CD19 CAR-expressing T-lymphocytes IC19/1563)

Recurrent B-Cell Non-Hodgkin Lymphoma; Recurrent Chronic Lymphocytic Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleAstraZenecaPhase 1

Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014 (Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014)

Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; Recurrent Diffuse Large B-Cell Lymphoma · EGFR

#EGFR#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Discontinued
CGTLimited DatastaleCity of Hope Medical CenterPhase 1

Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes (Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes)

Castration-Resistant Prostate Carcinoma; Metastatic Prostate Carcinoma · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

Autologous BCMA/CD19 dual-target CAR-T module (Autologous BCMA/CD19 dual-target CAR-T module)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleSeattle Children's HospitalPhase 1

Autologous CD19 CAR+ EGFTt + T cells (Autologous CD19 CAR+ EGFTt + T cells)

B Cell Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleJinbo ChenPreclinical

Autologous CD19 CAR-T cells (Autologous CD19 CAR-T cells)

Pemphigus Vulgaris · CD19

#CD19#CGT#Preclinical#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleRegional Blood Center of Ribeir…Phase 2

Autologous CD19-Directed CAR-T Cells Manufactured at Ribeirão Preto Blood Center (Autologous CD19-Directed CAR-T Cells Manufactured at Ribeirão Preto Blood Center)

Lupus Erythematosus, Systemic · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleHebei Senlang Biotechnology Inc…Phase 1

Autologous CD19-targeting CAR T cells (Autologous CD19-targeting CAR T cells)

Acute Lymphocytic Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleBeijing BiotechPhase 2

Autologous CD19/CD20 dual-target CAR-T module (Autologous CD19/CD20 dual-target CAR-T module)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

Autologous CD19/CD22 dual-target CAR-T module (Autologous CD19/CD22 dual-target CAR-T module)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 2

Autologous HuCD19 (Anti-CD19, Autologous HuCD19, Autologous HuCD19 ( Anti-CD19)CAR T cells)

Leukemia, Lymphocytic, Chronic, B-Cell; B-Lymphocytic Leukemia, Chronic · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastalePeking University People's Hosp…Phase 2

BCMA-CD19 CAR-T therapy (BCMA-CD19 CAR-T therapy)

Systemic Lupus Erythematosus; Inflammatory Myopathy · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleHebei Yanda Ludaopei HospitalPhase 1

BCMA/CD19 dual-target CAR-T cell immunotherapy (BCMA/CD19 dual-target CAR-T cell immunotherapy)

Multiple Myeloma · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleAllorunning TherapeuticsPhase 1

BCMA/CD19-targeted allogeneic CAR-T (BCMA/CD19-targeted allogeneic CAR-T)

Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma Patients Ineligible or Unwilling to Undergo ASCT; Newly Diagnose… · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting

5 / 11 pages

← PreviousNext →